Epizyme, a six-year-old, Cambridge, Mass.-based biopharmaceutical company that’s focused on researching treatments for tumors and blood cancer, has filed an S-1 with the SEC.

23andMe, Inc. said it raised more than $50 million in a Series D financing with new investor Yuri Milner joined by existing investors Google co-founder Sergey Brin, 23andMe CEO Anne Wojcicki, New Enterprise Associates, Google Ventures and MPM Capital. The company said the Series D investment, along with rapidly decreasing costs, allowed it to lower the price of its Personal Genome Service to $99,

Selexys Pharmaceuticals has completed a $23 million Series A equity financing, led by MPM Capital. Selexys has also entered into an agreement with Novartis Pharmaceuticals whereby Novartis has been granted an exclusive option to acquire Selexys and its lead asset, the anti-P-selectin antibody SelG1, following the successful completion of a Phase 2 clinical study in patients with sickle cell disease. Including upfront, acquisition and milestone payments, the agreement with Novartis could reach up to $665 million.

Astute Medical, the San Diego-based biomarker-based medical diagnostics firm, took in more than $40 million in a big Series C round, the company revealed. The financing was led by MPM Capital, and included new investor Kaiser Permanente Ventures. Prior backers De Novo Ventures, Delphi Ventures, Domain Associates and Johnson & Johnson Development Corporation also joined [...]

Aratana Therapeutics, a company developing medicines for companion animals, has closed on $15 million in Series B financing. The company, since its launch earlier this year, has raised a total of $31 million. Existing shareholders MPM Capital, Avalon Ventures and Cultivian Ventures contributed to the round, as did new investor the Ewing Marion Kauffman Foundation. The company is based in Kansas City, Kansas.

Verastem, a Cambridge, Mass.-based biopharmaceutical company focused on developing cancer-fighting drugs, has filed a registration statement with the SEC to go public. The number of shares and price range have not yet been determined. The 15-month-old company has raised $48 million in venture financing since its founding, including from Advanced Technology Ventures, MPM Capital, Bessemer [...]

Valeritas Inc., a Bridgewater, N.J.-based developer of drug delivery systems for the diabetes market, has raised $150 million in Series C financing. The funding will support commercialization of its V-Go disposable insulin delivery device. Welsh, Carson, Anderson & Stowe led the financing and assumes a controlling interest in Valeritas. Previous investors MPM Capital, Pitango Venture Capital, Abingworth Management, Advanced Technology Ventures, ONSET Ventures, HLM Venture Partners, Agate Medical Investments, CHL Medical Partners and Kaiser Permanente Ventures also participated.

Theraclone Sciences Inc. has added $10.6 million to its Series B round, closing the financing with a total of $41 million. ARCH Venture Partners, Canaan Partners, MPM Capital, Healthcare Ventures, Alexandria Real Estate Equities, Amgen Ventures and Zenyaku Kogyo participated in the financing. The money will be used to continue clinical and discovery programs.

Menlo Park, Calif.-based Nevro Corp., a neuromodulation company focused on relief of chronic pain, has sealed a whopping $58 million round led by new investor Johnson & Johnson Development Corporation. Existing shareholders Aberdare Ventures, Accuitive Medical Ventures, Bay City Capital, Mayo Clinic, MPM Capital and Three Arch Partners also participated. The money will go toward a clinical study in the US and to support the company’s commercialization strategy.

Boston-based Verastem has raised $32 million in Series B financing, only eight months after wrapping up a $16 million Series A round. Advanced Technology Ventures and Astellas Venture Management led the Series B, and were joined by all previous investors: Longwood Founders Fund, Bessemer Venture Partners, Cardinal Partners and MPM Capital. The money will support ongoing research and development. Verastem is and developing drugs to treat breast and other cancers by targeting cancer stem cells.